



# **VettaFi Weight Loss Drug & Treatment Index (THINR)**

# Table of Contents

- Introduction ..... 3
  - Index Objective ..... 3
  - Highlights ..... 3
  - Dates ..... 3
  - Supporting Documents ..... 3
- Eligibility Criteria and Index Construction ..... 4
  - Universe ..... 4
- Index Construction ..... 4
  - Constituent Selection ..... 4
  - Constituent Weightings & Constraints ..... 4
- Index Maintenance ..... 5
  - Rebalancing and Reconstitution ..... 5
  - Corporate Actions ..... 5
  - Index Information ..... 5
- Index Calculation ..... 6
- Index Governance ..... 6
- Index Policies ..... 6
- Contact Information ..... 6
- Disclaimer ..... 6
- Appendix ..... 7

## Introduction

### Index Objective

The VettaFi Weight Loss Drug & Treatment Index is an index of global companies expected to economically benefit from GLP-1 drug development, approval, or market adoption. This includes companies who are manufacturers in the GLP-1 pharmaceuticals business or are GLP-1 enablers. The index allocates 70% of its weight to a Principal Manufacturers segment and 30% to an Enablers segment.

### Highlights

The Manufacturers segment includes companies that have launched production or are in FDA clinical trials.

The Enablers segment includes companies active in outsourced work or other work that is a component of the GLP-1 market.

### Dates

Reference Dates: Last Business Date of month prior to Rebalance/Reconstitution Month.

Reconstitution Dates: Indexes reconstituted quarterly on the third Friday of the last month of each calendar quarter.

Weight Date: Thursday prior to second Friday of Rebalance/Reconstitution Month.

Rebalance Dates: Indexes are rebalanced quarterly on the third Friday of the last month of each calendar quarter.

## Supporting Documents

This methodology is meant to be read in conjunction with supporting documents providing greater detail with respect to the policies, procedures and calculations described herein.

The list of the main supplemental documents for this methodology can be found in the Methodologies and Governance tabs on the [Index Resources](#) page as follows:

Supporting Documents
Index Maintenance Policy
Index Governance
Index Policies
Methodology Policies
Glossary
Index Change and Consultation Policy

## Eligibility Criteria and Index Construction

### Universe

Constituents of countries in the VettaFi Full World Index (see Appendix) deemed to have sufficient access, liquidity, and foreign exchange markets for the trading needs of funds that support foreign investors. China constituents are restricted to Hong Kong listing and Depository Receipts. Indian shares are restricted to Depository Receipts.

### Index Construction

#### Constituent Selection

A company must be classified as a Drug Manufacturer or as an Enabler based on the following criteria:

Drug Manufacturers:

Companies with GLP-1 Agonist Drugs that are either launched or are in FDA clinical trials.

Enablers:

- Companies involved with the outsourced development and manufacturing of GLP-1 agonist drugs, also known as contract development and manufacturing organizations (CDMOs).
- Companies conducting measurement and analysis of GLP-1 agonist drugs.
- Companies involved in the distribution or administration of GLP-1 agonist drugs including coordination of prescriptions and drug-delivery mechanisms such as injection pens.

Additionally, all companies must meet the following criteria:

- Minimum Company Market Cap – 500 million USD
- Liquidity – 1 million USD 3-month ADTV (Average Daily Trading Volume)

#### Constituent Weightings & Constraints

Weights are float-market cap weighted within their segment allocation.

Drug Manufacturer Segment:

- 70% weight allocation
- Constituent caps
  - Companies at commercial or phase 3 stage: constituents capped at 15%
  - Companies at phase 2 or lower stage: constituents capped at 5%

Enabler Segment:

- 30% weight allocation
- Constituent caps
  - Constituents capped at 5%

Additionally, the sum of all constituent weights greater than 5% must be less than or equal to 45% of the total index. Capped weights are redistributed within their segment.

## Index Maintenance

### Rebalancing and Reconstitution

The Indexes are rebalanced on the “Rebalance Date” and additionally reconstituted on the “Reconstitution Date”. Pricing used in share weights used for reconstitutions are as of the “Weight Date”. Share weights for the rebalanced Indexes are computed as of the “Weight Date”. Changes to the Indexes related to the rebalances are as of the “Rebalance Date”. Additions are only made on reconstitution dates.

### Corporate Actions

Please refer to the Index Maintenance Policy document for information on Corporate Action processing.

### Index Information

Index history availability, base dates and base values are shown in the table below.

Index	Price Index	Base Date	Base Value	Total Return Index	Base Date	Base Value
VettaFi Weight Loss Drug & Treatment Index	THINR	06/18/21	1000	THINRT	06/18/21	1000

### Methodology Updates and Changes

Date	Version	Previous	New
Apr 2024	1.0.1	Name: VettaFi Weight Loss Drug Index	VettaFi Weight Loss Drug & Treatment Index
May 2024	1.0.2	Added clarification to Objective: Replaced: The VettaFi Weight Loss Drug Index is an index of global companies who are manufacturers in the GLP-1 pharmaceuticals business or who enable the business.	With: The VettaFi Weight Loss Drug & Treatment Index is an index of global companies expected to economically benefit from GLP-1 drug development, approval, or market adoption. This includes companies who are manufacturers in the GLP-1 pharmaceuticals business or are GLP-1 enablers
May 2024	1.0.2	Added Clarification to Enablers description: Replaced: Companies involved with the outsourced development and manufacturing of GLP-1 Agonist Drugs. This includes companies conducting measurement and analysis or other work that supports	With: <ul style="list-style-type: none"> <li>Companies involved with the outsourced development and manufacturing of GLP-1 agonist drugs, also known as contract development and manufacturing organizations (CDMOs).</li> <li>Companies conducting measurement and analysis of GLP-1 agonist drugs.</li> <li>Companies involved in the distribution or administration of GLP-1 agonist drugs</li> </ul>

		GLP-1 Agonist production and distribution.	including coordination of prescriptions and drug-delivery mechanisms such as injection pens.
Jun 2024	1.1.0	Constituents of the S-Network Developed World Equity 5000 Index (SNDW5K) or the VettaFi Developed World Index (VFDW).	Constituents of countries in the VettaFi Full World Index (see Appendix) deemed to have sufficient access, liquidity, and foreign exchange markets for the trading needs of funds that support foreign investors. China constituents are restricted to Hong Kong listing and Depository Receipts. Indian shares are restricted to Depository Receipts.
Jun 2024	1.1.0		Added 1 million USD 3-month ADTV liquidity requirement.

### Index Calculation

Please refer to the Index Maintenance Policy document for information on index calculations.

### Index Governance

The index is governed and managed by a VettaFi Index Committee for the purpose of meeting the goals of the index. For more information, please refer to the Index Governance document.

### Index Policies

Please refer to the Index Policies document for information regarding Announcements, Holiday Schedules, Unexpected Exchange Closures, and Recalculation Policy.

### Contact Information

For any questions regarding an index, please contact: [index.production@vetafi.com](mailto:index.production@vetafi.com)

### Disclaimer

The Indices are proprietary to VettaFi. No use or publication may be made of an Index, or any of its provisions or values, without the prior written consent of VettaFi. VettaFi is not responsible for any errors or omissions, regardless of the cause, for the results obtained from the use of the Content. In no event shall VettaFi be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of the Content.

## Appendix

### VettaFi Full World Index Countries

Australia	France	Malaysia	South Africa
Austria	Germany	Mexico	South Korea
Belgium	Greece	Netherlands	Spain
Brazil	Hong Kong	New Zealand	Sweden
Canada	Hungary	Norway	Switzerland
Chile	India	Peru	Taiwan
China	Indonesia	Philippines	Thailand
Colombia	Ireland	Poland	Turkey
Czech Republic	Israel	Portugal	United Arab Emirates
Denmark	Italy	Qatar	United Kingdom
Egypt	Japan	Saudi Arabia	United States
Finland	Kuwait	Singapore	